anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to a method for inducing a customized totipotent stem cell induced by reprogramming a differentiated adult cell using shikimic acid, a plant extract or a plant stem cell comprising shikimic acid, and an extract of a redifferentiated plant stem cell (callus), a totipotent stem cell prepared by the method, and a composition comprising the totipotent stem cell. According to the present invention, since a totipotent stem cell having the same ability as an embryonic stem cell is not prepared using an ovum, the moral problem can be solved. Most importantly, by using a plant stem cell extract that has been proven to be harmless to humans, totipotent stem cells with secured safety can be prepared. In addition, the present invention can be used to develop an immunologically compatible cellular therapeutic agent tailored specifically to a subject. Furthermore, by inducing totipotent stem cells from a subject suffering from a disease, the present invention can be very useful for the study of therapeutic methods and diagnosis of etiology. Furthermore, the present invention relates to a composition comprising shikimic acid or a plant extract containing shikimic acid.
<P>PROBLEM TO BE SOLVED: To provide a method for efficiently extracting active ingredients contained in Verbena officinalis, while preventing that the active ingredients are lost by heating or a production cost is increased by using an organic solvent.  <P>SOLUTION: This health food is obtained by immersing dried Verbena officinalis in edible vinegar for approximately 1 month and removing solid materials by squeezing with a press to make liquid portion as a product. Based on 100 pts.mass edible vinegar, 2-0.5 pts.mass dried Verbena officinalis is immersed. The standard amount of daily intake is set as 30 cc, and it may be taken by 30 cc for one time daily or may be taken by 10 cc each for 3 times a day. Also, it may be taken by diluting with water suitably.  <P>COPYRIGHT: (C)2007,JPO&INPIT
Stage two is a parallel, randomized, double-blind, double-dummy study. Non-responders underwent 2-week washout period and were randomly assigned to groups receiving Oxymetazoline and placebo.
Sleep is a fundamental state for maintaining the organism homeostasis. Disruptions in sleep patterns predispose to the appearance of memory impairments and mental disorders, including depression. Recent pre-clinical studies have highlighted the antidepressant-like properties of the synthetic compound 2-phenyl-3-(phenylselanyl)benzofuran (SeBZF1). To further investigate the neuromodulatory effects of SeBZF1, this study aimed to assess its therapeutic efficacy in ameliorating neurobehavioral impairments induced by sleep deprivation (SD) in mice. For this purpose, a method known as multiple platforms over water was used to induce rapid eye movement (REM) SD. Two hours after acute SD (24 h), male Swiss mice received a single treatment of SeBZF1 (5 mg/kg, intragastric route) or fluoxetine (a positive control, 20 mg/kg, intraperitoneal route). Subsequently, behavioral tests were conducted to assess spontaneous motor function (open-field test), depressive-like behavior (tail suspension test), and memory deficits (Y-maze test). Brain structures were utilized to evaluate oxidative stress markers, monoamine oxidase (MAO) and acetylcholinesterase (AChE) activities. Our findings revealed that SD animals displayed depressive-like behavior and memory impairments, which were reverted by SeBZF1 and fluoxetine treatments. SeBZF1 also reverted the increase in lipoperoxidation levels and glutathione peroxidase activity in the pre-frontal cortex in mice exposed to SD. Besides, the increase in hippocampal AChE activity induced by SD was overturned by SeBZF1. Lastly, cortical MAO-B activity was reestablished by SeBZF1 in mice that underwent SD. Based on the main findings of this study, it can be inferred that the compound SeBZF1 reverses the neurobehavioral alterations induced by sleep deprivation in male Swiss mice.
PURPOSE: Invasive ventilation is a fundamental treatment in intensive care but its precise timing is difficult to determine. This study aims at assessing the effect of initiating invasive ventilation versus waiting, in patients with hypoxemic respiratory failure without immediate reason for intubation on one-year mortality.
METHODS: Emulation of a target trial to estimate the benefit of immediately initiating invasive ventilation in hypoxemic respiratory failure, versus waiting, among patients within the first 48-h of hypoxemia. The eligible population included non-intubated patients with SpO2/FiO2 ≤ 200 and SpO2 ≤ 97%. The target trial was emulated using a single-center database (MIMIC-IV) which contains granular information about clinical status. The hourly probability to receive mechanical ventilation was continuously estimated. The hazard ratios for the primary outcome, one-year mortality, and the secondary outcome, 30-day mortality, were estimated using weighted Cox models with stabilized inverse probability weights used to adjust for measured confounding.
RESULTS: 2996 Patients fulfilled the inclusion criteria of whom 792 were intubated within 48 h. Among the non-invasive support devices, the use of oxygen through facemask was the most common (75%). Compared to patients with the same probability of intubation but who were not intubated, intubation decreased the hazard of dying for the first year after ICU admission HR 0.81 (95% CI 0.68-0.96, p = 0.018). Intubation was associated with a 30-day mortality HR of 0.80 (95% CI 0.64-0.99, p = 0.046).
CONCLUSION: The initiation of mechanical ventilation in patients with acute hypoxemic respiratory failure reduced the hazard of dying in this emulation of a target trial.
With the increase in age, the oral function of older adults shows an age-related decline, which limits the types, quantity, and quality of their diet. Limited dietary intake can lead to a lack of basic nutrients needed for maintaining oral health, induce a series of oral diseases, and further aggravate the deterioration of oral functions. Oral frailty is the accumulation of mild oral function decline and is an emerging concept in the field of oral health. Currently, research on oral frailty and dietary intake mostly focuses on the impact of single-dimensional oral function decline on the dietary intake, dietary structure, and dietary satisfaction of older adults, as well as the impact of different dietary structures on the status of oral health among older adults. There is still a lack of large-sample, high-quality research on the relationship between comprehensive oral function decline and dietary intake. In addition, existing oral frailty intervention measures often place a narrow emphasis on the exercise and recovery of oral function without considering the impact of dietary intake and nutritional status on the development of oral frailty. Relevant research on taking dietary intake as an entry point or using it as a comprehensive intervention method also needs to be further explored by researchers. In the future, specialized assessment and screening of dietary status may be introduced in the routine health management practices for older adults. Furthermore, targeted intervention programs could also be proposed based on the characteristics of the oral status and the dietary intake habits of older adults, so as to prevent the functional decline related to dietary intake and nutritional supplementation. Herein, we reviewed the correlation between dietary intake and oral frailty to provide new ideas and directions for formulating comprehensive management strategies for oral frailty.
. Technical Result Increase in neurological diseases. 2. Essence A liquid pharmaceutical composition of a GABA analog comprising at least one polyhydric alcohol containing 2 to 6 carbon atoms, the contents of polyhydric alcohol in the composition being 25-75 (mass/vol)%, having a pH of about 5.5 to about 7.0 and additionally a two-component liquid pharmaceutical composition comprising a first component comprising a GABA analog and a solid polyhydric alcohol, and a second component comprising a liquid base are described; methods to prepare the compositions and pharmaceutical compositions used for treating cerebral diseases, including epilepsy, faintness attacks, hypokinesia, neurodegenerative disorders, depression, mania and bipolar disorders, anxiety, panic, inflammation and other diseases. 3. Field of Application Medicine. Tables: 2
Inactive ingredients include: microcrystalline cellulose, NF, mannitol, USP, croscarmellose sodium, NF, magnesium stearate, NF and lake blend blue. 

HYOSCYAMINE SULFATE is an alkaloid of belladonna. Exists as a white crystalline powder. Affected by light. It is very soluble in water; freely soluble in alcohol; practically insoluble in ether.

METHENAMINE exists as colorless, lustrous crystals or white crystalline powder. Its solutions are alkaline to litmus. Freely soluble in water; soluble in alcohol and in chloroform.

METHYLENE BLUE exists as dark green crystals. It is soluble in water and in chloroform; sparingly soluble in alcohol.

MONOBASIC SODIUM PHOSPHATE exists as a white crystalline powder. Its solutions are acidic to litmus. It is freely soluble in water and practically insoluble in alcohol.
The technical result of the invention is in practical realization of a highly effective remineralization composition using available and cheap components. Said composition owing to a lack of fluoride can be recommended to patients with signs of fluorosis, diseases of endocrine system for prophylaxis of caries and non-carious lesions. The composition comprises acceptable active components and inert components. Among the active components the composition comprises a complex consisting of sources of magnesium, sodium, silicon and potassium elements in an amount of 1-11 mass %. The ratio of atomic masses of magnesium, sodium, silicon and potassium elements of the active components complex correspondingly is 21.3:9.3:1.67:1. Magnesium chloride or magnesium glycerophosphate, or magnesium citrate is used as the source of magnesium element. Sodium chloride or sodium silicate are used as the sources of sodium element. Sodium metasilicate or potassium metasilicate are used as the sources of silicon element, and potassium silicate is used as the source of potassium element.
Patients diagnosed as hepatocellular carcinoma will be randomly assigned for treatment with Lenvatinib. Cap. Lenvatinib will be given at doses of 4 mg 12 hourly.
BACKGROUND: Nanoparticles (NPs) are a class of substances that can be loaded with therapeutic agents delivered to specific areas. In our earlier research, we identified a neuron-derived circular RNA (circRNA), circular oxoglutarate dehydrogenase (CircOGDH), as a promising therapeutic target for acute ischaemic stroke. This study dedicated to explore a prospective preliminary strategy of CircOGDH-based NP delivered to the ischaemic penumbra region in middle cerebral artery occlusion/reperfusion (MCAO/R) mice.
METHODS: Immunofluorescence in primary cortex neurons and in vivo fluorescence imaging revealed endocytosis of Poly(lactide-co-glycolide) (PLGA) poly amidoamine(PAMAM)@CircOGDH small interfering RNA (siRNA) NPs. Western blotting analysis and CCK8 assay were performed to evaluate the apoptotic level in ischaemic neurons treated with PLGA-PAMAM@CircOGDH siRNA NPs. Quantitative reverse transcription PCR experiments, mice behaviour test, T2 MRI analysis, Nissl and TdT-mediated dUTP nick end labeling (TUNEL) co-staining were performed to evaluate the apoptosis level of ischaemic penumbra neurons in MCAO/R mice. Biosafety evaluation of NPs in MCAO/R mice was detected by blood routine examination, liver and kidney function examination and HE staining.
RESULTS: PLGA-PAMAM@CircOGDH siRNA NPs were successfully assembled. Endocytosis of PLGA-PAMAM@CircOGDH siRNA NPs in ischaemic neurons alleviated neuronal apoptotic level in vitro and in vivo. Furthermore, mice behaviour test showed that the neurological defects of MCAO/R mice were significantly alleviated after the tail injection of PLGA-PAMAM@CircOGDH siRNA NPs, and no toxic effects were observed.
CONCLUSION: In conclusion, our results suggest that PLGA-PAMAM@CircOGDH siRNA NPs can be delivered to the ischaemic penumbra region and alleviate neuron apoptosis in MCAO/R mice and in ischaemic neurons; therefore, our study provides a desirable approach for using circRNA-based NPs for the treatment of ischaemic stroke.
PURPOSE:To obtain a colorless pottery material which has high strength and high purity, has no structural defects, does not decompose and form whitlock stone in spite of calcination at a specific temp. and has improved stability by calcining the dried body of the filter cake of synthetic hydroxyapatite of a stoichiometrical compsn. having specific characteristics. CONSTITUTION:The emulsion of particulate calcium hydroxide formed by bringing porous particulate calcium oxide and excess water into reaction and an aq. phosphoric acid soln. are brought into reaction in an inert atmosphere to obtain the hydroxyapatite(HAP). This uncalcined HAP has the characteristics of 1.67 to 1.69 Ca/P element ratio, 187 to 1200Angstrom  length of average crystal size, 50 to 320Angstrom  width and 3.75 to 10 length/width. The dried body of the filter cake of the HAP having 0.2 to 0.8cm<3>/g voids and 50 to 150Angstrom  average pore radius between the crystals is obtd. if the suspension-like reaction liquid contg. such HAP is rinsed and dried. The formation of the whitlock stone is not admitted even if this dried body is calcined for one hour at 1350 deg.C.
Ultrasound-guided scalp block performed for supraorbital nerve, supratrochlear nerve, zygomaticotemporal nerve, auriculotemporal nerve, superficial cervical plexus, greater occipital nerve and third occipital nerve. The local anaesthetic used will be ropivacaine 0.375%.
The recent article "Clinical characteristics and outcomes after trigeminal schwannoma resection: a multi-institutional experience" by Nandoliya et al. offers critical insights into the management of trigeminal schwannomas (TS). This multi-institutional study, encompassing 30 patients over 18 years, highlights various surgical approaches, achieving gross-total resection in 53% of cases, and emphasizes the balance between resection and neurological preservation. The use of intraoperative neuromonitoring in 77% of cases is noted for minimizing morbidity. Despite a 13% complication rate, most were transient. Long-term follow-up data show a low recurrence rate, advocating for ongoing surveillance. The study underscores the importance of tailored surgical strategies, and the discussion of classification systems aids in contextual understanding. While the findings are robust, further research into adjuvant therapies and emerging technologies is warranted. This comprehensive overview advances our understanding of TS, promoting a patient-centered approach to surgical management.
This research will occur in two centers Kernan Orthopedics and Rehabilitation Hospital in Baltimore, Maryland and Shepherd Center in Atlanta, Georgia. A total of 36 volunteers over a three year period are needed. In order to qualify for this study, individuals must be 18 to 65 years old with a motor incomplete SCI. The level of injury can range from the fourth cervical level in the neck to the twelfth thoracic level in the back. Potential volunteers must be able to tolerate standing in a standing frame for at least 30 minutes. Individuals will be assessed by a physician to determine their eligibility for the study and if participating in this type of exercise would be safe. Participants must be able to understand the study requirements and sign an informed consent document.

Participants will need to commit to a total of seven months. Included in this time is: testing, then the 3 months of exercise, testing, 2 week break, then the second 3 months of exercise, and a final testing. Half of the group will start with the Lokomat training and half will start wtih aquatic exercise. Each group will then switch to the other exercise condition. Exercise sessions will occur three times per week and last approximately 45-55 minutes. A physical therapist will provide personal direction for each of the exercise groups. Walking ability and cardiovascular fitness, as well as muscle strength will be assessed before starting exercise, at the three-month point and then at the six month point.

It is hoped that that this type of exercise therapy will help individuals with motor incomplete spinal injury both walk better and experience better heart-lung fitness and endurance. The risks associated with this type of study are similar to any type of cardiovascular exercise. In addition, individuals with spinal cord injury may present with some medical conditions, there may be other risks of the study. The physicians and therapists involved in the research will discuss these risks in detail with the individuals who enroll.

This type of research is important to better understand how best to prescribe exercise treatments to people with spinal injury. This is especially true with regards to aquatic therapy, since there is very little scientific data on its effect in this group of individuals. The rigorous assessment of aquatic exercise, which is already available in many communities, may expand the fitness opportunities for individuals with incomplete spinal cord injury.
The invention belongs to the technical field of biological medicine. The invention provides a preparation method and application of a physical crosslinking double-sensitive composite carrier hydrogel. The composite hydrogel consists of oxidized nanocellulose (TOCN), polyvinyl alcohol (PVA) and a Polydopamine (PDA) coating. Wherein the content of oxidized cellulose can significantly affect the performance of the composite hydrogel. Through reasonable design, the optimal addition amount is selected, the composite hydrogel (TOCN/PVA 7) is obtained through physical crosslinking by a cyclic freeze thawing method, and then the TOCN/PVA7-PDA is formed through rapid encapsulation of polydopamine, so that the composite hydrogel can be used as a carrier of various small-molecule medicines. In vitro studies show that TOCN/PVA7-PDA hydrogel has obvious photo-thermal effect and pH response release. Can be used for in-situ temperature and pH response release of loaded small molecule drugs.
The invention discloses a pharmaceutical composition for prevention and treatment of mesenterium proliferation acute nephritis and focal glomeruloscerosis and a preparation method of the pharmaceutical composition. The pharmaceutical composition is formed by compatibility of extractives of astragalus, panax notoginseng and salviae miltiorrhizae, and effective constituents are flavonoid, saponins and phenolic acid. Medicine materials comprise, by weight, 9-30 parts of the astragalus, 3-10 parts of the panax notoginseng, and 3-20 parts of the salviae miltiorrhizae. Salviae miltiorrhizae contents of all kinds of chemical components include that when calycosin serves as a reference substance, the total flavonoid content is 30.0-0.50%; when total saponins of the panax notoginseseng serves as a reference substance, the total saponins content is 18.0-97.0%; and when caffeic acid serves as a reference substance, the total phenolic acid content is 52.0-2.5%. The inventor of the pharmaceutical composition and the preparation method combines disease-based medicine with vidence-based medicine in long-term clinic treatment. Efficacy of the pharmaceutical composition is superior to single use of any one medicinal component or combined use of two medicinal components. The pharmaceutical composition is little in toxicity and suitable for long-term taking.
The objective of this study was to evaluate the effects and economic viability of diets containing different levels of antibiotic and buriti oil (BO) on performance, carcass and cut yields, and relative weight of organs of broilers. A total of 432 one- to 42-day-old male chicks were distributed in a completely randomized experimental design with six treatments, each consisting of six replicates of 12 birds. The treatments consisted of one diet with antibiotic without BO, one diet without antibiotic (DWA) without BO, and four DWA containing increasing levels of BO (0.2, 0.4, 0.6, and 0.8%). Average weight and weight gain (WG) of broilers fed with DWA + BO were similar to those of birds fed control diet. Feed intake and feed conversion (FC) were not different among treatments. Relative weight of pancreas linearly increased in the birds fed diets containing BO. The inclusion of 0.45 and 0.40% of BO in the diets promoted the improvement of WG and FC, respectively. Cost of feed management, ratio, gross margin, and gross income did not differ among treatments. It was concluded that the inclusion of 0.45% of BO in diets without antibiotics is economically feasible and allows recovering the performance of broilers.
PROBLEM TO BE SOLVED: To provide amorphous rifaximin useful for treatments of intestinal diseases such as diarrhea, traveler diarrhea, microorganism-related diarrhea, Crohn's disease, chronic pancreatitis, pancreatic insufficiency and/or colitis, and having improved dissolution rate, and a manufacturing method therefor.SOLUTION: There is provided a manufacturing method of rifaximin with an amorphous form, characterized by an XRPD pattern shown in Figure 1 by following a) to h). a) Rifamycin S is reacted with 2-amino-4-picoline. b) Iodine and continuously a reductant are added. c) PH of a reaction mass is adjusted between 1.5 to 2.5 under stirring. d) Extraction with an organic solvent is conducted and an organic layer is concentrated. e) A residual obtained in the process d) is tripped with n-heptane to generate a residual. f) The residual obtained in the process e) is stirred together with dichloromethane, heptane or a mixture thereof to obtain a solid. g) The solid is filtrated and washed with a solvent. h) The solid is dried at a temperature of less than 40°C.SELECTED DRAWING: Figure 1
Carbamazepine extended-release capsules is an anticonvulsant and specific analgesic for trigeminal neuralgia, available for oral administration as 100 mg, 200 mg and 300 mg extended-release capsules of Carbamazepine, USP. Carbamazepine is a white to off-white powder, practically insoluble in water and soluble in alcohol and in acetone. Its molecular weight is 236.27. Its chemical name is 5H-dibenz[b,f]azepine-5-carboxamide, and its structural formula is:

Carbamazepine extended-release capsules are composed of an extended-release matrix granulation.

Inactive ingredients: ammonio methacrylate copolymer, colloidal silicon dioxide, magnesium stearate, microcrystalline cellulose, sodium starch glycolate and triethyl citrate. 

The 100 mg and 200 mg capsule shells contain FD&C Blue 1, gelatin, iron oxide yellow, sodium lauryl sulfate and titanium dioxide, and are imprinted with black ink. The 300 mg capsule shells contain gelatin, sodium lauryl sulfate and titanium dioxide, and are imprinted with black ink.
In this arm, patients will be provided with N115 sodium pyruvate nasal spray and instructed to use it 3x daily for 14 days. This group will be compared to the placebo control group to determine if sodium pyruvate reduces the symptoms, duration and replication of COVID-19 infection.